Donepezil Hydrochloride Ranbaxy (Uk) (Donepezil Hydrochloride)

Donepezil Hydrochloride Ranbaxy (Uk) is indicated for the symptomatic treatment of cognitive decline associated with Alzheimer’s disease. It may be prescribed for patients with mild to moderate stages of the condition and is sometimes used off‑label for other types of dementia.

• Improves memory and attention in Alzheimer’s disease patients.
• May delay functional decline in mild to moderate disease.
• Used as part of a comprehensive dementia management plan.
• Can be considered when cholinergic support is clinically appropriate.
• May be prescribed alongside non‑pharmacologic therapies.

Side effects of Donepezil Hydrochloride Ranbaxy (Uk) vary in frequency and severity. Common reactions are usually mild and transient, while serious adverse events require medical attention.

Common

• Nausea or vomiting
• Diarrhea
• Insomnia or vivid dreams
• Loss of appetite
• Muscle cramps or weakness
• Fatigue

Serious

• Bradycardia or heart block
• Severe gastrointestinal bleeding
• Seizures
• Hepatotoxicity (liver enzyme elevation)
• Allergic reactions such as rash or angioedema

When prescribing Donepezil Hydrochloride Ranbaxy (Uk), clinicians should consider several precautionary measures to ensure patient safety.

• Assess cardiac history; avoid in patients with sick sinus syndrome.
• Monitor liver function tests periodically.
• Use cautiously in patients with a history of seizures.
• Adjust dose in renal impairment as recommended.
• Review concomitant medications that affect heart rate.
• Counsel patients on potential gastrointestinal side effects.
• Advise against abrupt discontinuation without medical guidance.

Donepezil Hydrochloride Ranbaxy (Uk) can interact with other drugs, influencing its efficacy or safety profile. Some combinations should be avoided, while others require careful monitoring.

Avoid

• Anticholinergic agents (e.g., diphenhydramine) that may counteract therapeutic effects.
• Beta‑blockers or calcium channel blockers that may exacerbate bradycardia.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) increasing risk of GI bleeding.

Use with caution

• Other cholinesterase inhibitors (e.g., rivastigmine) – risk of additive side effects.
• CYP3A4 inhibitors (e.g., ketoconazole) – may increase donepezil levels.
• CYP2D6 inhibitors (e.g., fluoxetine) – may affect metabolism.
• Drugs that prolong QT interval – monitor cardiac rhythm.